News for Veru Inc. (VERU)

MIAMI, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Veru Inc. ( VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines fo

\n Veru Inc. (VERU) is set to present at the 2nd Annual GLP-1-Based Therapeutics Summit in Boston, showcasing their Phase 2b QUALITY Clinical Study. The pr

**media[581342]**

After losing some value lately, a hammer chart pattern has been formed for Veru (VERU), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

The heavy selling pressure might have exhausted for Veru (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Discover Veru Inc's Q1 2025 progress as it transitions into a biopharma focus.

Veru Inc (NASDAQ:VERU) Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor Relations...

Revenue: Reported revenue of $1.28 million, aligning with the estimated revenue for the quarter.Earnings Per Share (EPS): Achieved EPS of -$0.01, surpassing th

--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of pr

On December 31, 2024, ADAGE CAPITAL PARTNERS GP, L.L.C. (Trades, Portfolio) executed a significant reduction in its holdings of Veru Inc. The firm decreased its

Veru Inc (VERU) is set to release its Q1 2025 earnings on Feb 13, 2025. The consensus estimate for Q1 2025 revenue is $3.02 million, and the earnings are expect

U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling over 100 points on Monday. The Dow traded up 0.22% to 44,521.81 while the NASDAQ f...

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index edging higher on Monday. The Dow traded up 0.04% to 44,440.59 while the NASDAQ...

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 600 points on Monday. Following the market opening Monday, the Dow traded down 0....

-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.00

**media[524941]**

Does Veru Inc. (VERU) have what it takes to be a top stock pick for momentum investors? Let's find out.

SWK Holdings updates on recent financial activities

Veru Inc. (NASDAQ:VERU) shares jumped on Tuesday after the company disclosed the sale of its FC2 Female Condom (Internal Condom) business to clients managed by Riva Ridge Capital Management LP and co-investors for $18 million. As a result of the FC2 business sale, Veru’s workforce will be reduced by approximately 90%, from 210 employees to 22. After deducting the change of control premium to SWK Funding LLC under the company's Residual Royalty Agreement, along with customary transaction fees, Ve